¼¼°èÀÇ EÇü °£¿° Áø´Ü °Ë»ç ½ÃÀå
Hepatitis E Diagnostic Tests
»óǰÄÚµå : 1786682
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 285 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,150,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,452,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

EÇü °£¿° Áø´Ü °Ë»ç ¼¼°è ½ÃÀåÀº 2030³â±îÁö 6,780¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 5,540¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â EÇü °£¿° Áø´Ü °Ë»ç ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 3.4%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 6,780¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ELISA HEV IGM °Ë»ç À¯ÇüÀº CAGR 4.8%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á±îÁö 2,960¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ELISA HEV IGG °Ë»ç À¯Çü ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 2.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 1,510¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ÇÑÆí Áß±¹Àº CAGR 6.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ´Â

¹Ì±¹ÀÇ EÇü °£¿° Áø´Ü °Ë»ç ½ÃÀåÀº 2024³â¿¡ 1,510¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 1,370¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 6.6%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 1.3%¿Í 2.7%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è EÇü °£¿° Áø´Ü °Ë»ç ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

EÇü °£¿° Áø´ÜÀÌ Àü ¼¼°èÀûÀ¸·Î ÁÖ¸ñ¹Þ´Â ÀÌÀ¯´Â?

EÇü °£¿° ¹ÙÀÌ·¯½º(HEV)¿¡ ÀÇÇÑ °£ °¨¿° ÁúȯÀÎ EÇü °£¿°Àº ±ú²ýÇÑ ¹°°ú À§»ý½Ã¼³¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Á¦ÇÑµÈ °³¹ßµµ»ó±¹À» Áß½ÉÀ¸·Î °øÁߺ¸°Ç ¹®Á¦°¡ ´ëµÎµÇ°í ÀÖ½À´Ï´Ù. ÀÌ Áúº´Àº ÁÖ·Î ¿À¿°µÈ ¼ö¿øÀ» ÅëÇØ ÀüÆÄµÇ±â ¶§¹®¿¡ ÀÎÇÁ¶ó°¡ Àß °®Ãß¾îÁöÁö ¾ÊÀº ±¹°¡¿¡¼­´Â Å« ¹®Á¦°¡ µÇ°í ÀÖ½À´Ï´Ù. Áø´Ü °Ë»ç´Â HEV °¨¿°À» °¨ÁöÇϰí, Àû½Ã¿¡ Ä¡·á¸¦ ÃËÁøÇϰí, ¹ßº´À» ¿¹¹æÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. EÇü °£¿°ÀÌ À¯Çà Áö¿ª°ú ºñÀ¯Çà Áö¿ª ¸ðµÎ¿¡¼­ È®»êµÊ¿¡ µû¶ó Á¤È®ÇÏ°í ½Å¼ÓÇÑ Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¤ºÎ¿Í ÀÇ·á ±â°üÀº HEVÀÇ È®»êÀ» ¿ÏÈ­Çϱâ À§ÇØ ¼±º° °Ë»ç ÇÁ·Î±×·¥¿¡ ÅõÀÚÇϰí ÀÖÀ¸¸ç, ÀÌ´Â EÇü °£¿° Áø´Ü °Ë»ç ½ÃÀåÀÇ È®´ë¸¦ ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

±â¼ú Çõ½ÅÀº EÇü °£¿° Áø´ÜÀ» ¾î¶»°Ô °³¼±Çϰí Àִ°¡?

EÇü °£¿° Áø´Ü ½ÃÀåÀº Ç÷ûÇÐÀû ºÐ¼®, ÁßÇÕÈ¿¼Ò ¿¬¼â ¹ÝÀÀ(PCR) ±â¼ú, ÇöÀå °Ë»ç ¼Ö·ç¼ÇÀÇ °³¼±À¸·Î ±Þ¼ÓÇÑ ±â¼ú ¹ßÀüÀ» ¸ñ°ÝÇϰí ÀÖ½À´Ï´Ù. È¿¼Ò °áÇÕ ¸é¿ª ÈíÂø ÃøÁ¤¹ý(ELISA)ÀÇ °³¹ß·Î HEV Ç×üÀÇ °ËÃâ Á¤È®µµ¿Í È¿À²¼ºÀÌ Çâ»óµÇ¾î Á¶±â Áø´Ü ¹× Áúº´ ¸ð´ÏÅ͸µÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ¶ÇÇÑ, ½Ç½Ã°£ PCR µî ºÐÀÚÁø´Ü ±â¼úÀÇ µµÀÔÀ¸·Î HEV RNAÀÇ Á¤È®ÇÑ µ¿Á¤ÀÌ °¡´ÉÇØÁ® ±Þ¼º °¨¿°°ú ¸¸¼º °¨¿°ÀÇ °¨º°¿¡ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ½Å¼Ó °Ë»ç ŰƮÀÇ µîÀåÀº ƯÈ÷ ÀÚ¿øÀÌ ºÎÁ·ÇÑ È¯°æ¿¡¼­ EÇü °£¿° Áø´Ü¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» ´õ¿í Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀ» ÅëÇØ EÇü °£¿° °Ë»çÀÇ ½Å·Ú¼º°ú Á¢±Ù¼ºÀ» Çâ»ó½ÃÄÑ Áúº´ °ü¸® °³¼±¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

EÇü °£¿° Áø´Ü °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

EÇü °£¿° ¹ßº´·ü Áõ°¡, Àü ¼¼°è ¿©Çà°´ Áõ°¡, ¹ÙÀÌ·¯½º¼º °£¿°¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ EÇü °£¿° Áø´Ü °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¤ºÎ¿Í ÀÇ·á±â°üÀº HEV °¨¿°¿¡ µû¸¥ ÇÕº´ÁõÀ» ¿¹¹æÇϱâ À§ÇØ ÀÓ»êºÎ, ¸é¿ª°áÇÌÀÚ µî °íÀ§Ç豺À» ´ë»óÀ¸·Î ¼±º°°Ë»ç ÇÁ·Î±×·¥À» ½ÃÇàÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ³óÃÌ Áö¿ª¿¡¼­ÀÇ ÇöÀå Áø´Ü È®´ëµµ Áúº´ ¹ß°ß ¹× °ü¸® °³¼±¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Áø´Ü ÀÚµ¿È­ÀÇ ¹ßÀüÀ¸·Î ¼Ò¿ä½Ã°£ÀÌ ´ÜÃàµÇ¾î ÀÓ»óÇöÀå¿¡¼­ ½Å¼ÓÇÑ ÀÇ»ç°áÁ¤ÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. Àü ¼¼°è º¸°Ç±â°üÀÌ °£¿° ¿¹¹æ°ú ÅëÁ¦¸¦ ÃÖ¿ì¼± °úÁ¦·Î »ï°í ÀÖ´Â °¡¿îµ¥, HEV Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä´Â Å©°Ô Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

EÇü °£¿° Áø´Ü °Ë»ç ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?

EÇü °£¿° Áø´Ü °Ë»ç ½ÃÀåÀÇ ¼ºÀåÀº Áúº´ À¯º´·ü Áõ°¡, Áø´Ü ±â¼ú ¹ßÀü, ¹ÙÀÌ·¯½º¼º °£¿° °¨½Ã¸¦ °³¼±Çϱâ À§ÇÑ Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê¿¡ ±âÀÎÇÕ´Ï´Ù. ¶ÇÇÑ, ½ÅÈï±¹ÀÇ ÀÇ·á ÀÎÇÁ¶ó È®´ëµµ °£¿° °Ë»ç¿¡ ´ëÇÑ Á¢±Ù¼º È®´ë¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, º¸´Ù ½Å¼ÓÇϰí Á¤È®ÇÑ Áø´Ü ¼Ö·ç¼ÇÀÇ ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡Çϰí ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. °øÁߺ¸°Ç Àü·«ÀÌ ¹ÙÀÌ·¯½º¼º °£¿°ÀÇ Á¶±â ¹ß°ß°ú ¿¹¹æ¿¡ ÃÊÁ¡À» ¸ÂÃß°í Àֱ⠶§¹®¿¡ EÇü °£¿° Áø´Ü °Ë»ç ½ÃÀåÀº Å©°Ô È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÎ¹®

À¯Çü(ELISA HEV IGM °Ë»ç À¯Çü, ELISA HEV IGG °Ë»ç À¯Çü, ½Å¼Ó Áø´Ü °Ë»ç À¯Çü, ÁßÇÕÈ¿¼Ò ¿¬¼â ¹ÝÀÀ À¯Çü), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø ÃÖÁ¾»ç¿ëÀÚ, Áø´Ü ¿¬±¸¼Ò ÃÖÁ¾»ç¿ëÀÚ, Ç÷¾×ÀºÇà ÃÖÁ¾»ç¿ëÀÚ, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹üÀ» µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡°¡ ¼±º°ÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Hepatitis E Diagnostic Tests Market to Reach US$67.8 Million by 2030

The global market for Hepatitis E Diagnostic Tests estimated at US$55.4 Million in the year 2024, is expected to reach US$67.8 Million by 2030, growing at a CAGR of 3.4% over the analysis period 2024-2030. ELISA HEV IGM Tests Type, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$29.6 Million by the end of the analysis period. Growth in the ELISA HEV IGG Tests Type segment is estimated at 2.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$15.1 Million While China is Forecast to Grow at 6.6% CAGR

The Hepatitis E Diagnostic Tests market in the U.S. is estimated at US$15.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$13.7 Million by the year 2030 trailing a CAGR of 6.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global Hepatitis E Diagnostic Tests Market - Key Trends & Drivers Summarized

Why Is Hepatitis E Diagnosis Gaining Global Attention?

Hepatitis E, a liver infection caused by the hepatitis E virus (HEV), is becoming an increasing public health concern, particularly in developing regions with limited access to clean water and sanitation. The disease primarily spreads through contaminated water sources, making it a significant challenge in countries with poor infrastructure. Diagnostic tests play a crucial role in detecting HEV infections, facilitating timely treatment, and preventing outbreaks. The growing prevalence of hepatitis E in both endemic and non-endemic regions has heightened the demand for accurate and rapid diagnostic solutions. Governments and healthcare organizations are investing in screening programs to mitigate the spread of HEV, driving the expansion of the hepatitis E diagnostic tests market.

How Are Technological Innovations Improving Hepatitis E Diagnostics?

The hepatitis E diagnostic market is witnessing rapid technological advancements, with improvements in serological assays, polymerase chain reaction (PCR) techniques, and point-of-care testing solutions. The development of enzyme-linked immunosorbent assays (ELISA) has enhanced the accuracy and efficiency of detecting HEV antibodies, allowing for early diagnosis and disease monitoring. Additionally, the introduction of molecular diagnostic techniques, such as real-time PCR, has enabled precise identification of HEV RNA, aiding in the differentiation of acute and chronic infections. The emergence of rapid test kits is further improving access to hepatitis E diagnostics, particularly in resource-limited settings. These innovations are enhancing the reliability and accessibility of hepatitis E testing, contributing to improved disease control efforts.

Why Is the Demand for Hepatitis E Diagnostic Tests Increasing?

The rising incidence of hepatitis E infections, increasing global travel, and growing awareness about viral hepatitis have fueled the demand for hepatitis E diagnostic tests. Governments and healthcare agencies are implementing screening programs in high-risk populations, such as pregnant women and immunocompromised individuals, to prevent complications associated with HEV infections. The expansion of point-of-care diagnostics in rural areas has also contributed to improved disease detection and management. Additionally, advancements in diagnostic automation are reducing turnaround times, enabling faster decision-making in clinical settings. As global health organizations prioritize hepatitis prevention and control, the demand for HEV diagnostic solutions is expected to grow significantly.

What Are the Key Factors Driving the Growth of the Hepatitis E Diagnostic Tests Market?

The growth in the hepatitis E diagnostic tests market is driven by increasing disease prevalence, advancements in diagnostic technologies, and government initiatives aimed at improving viral hepatitis surveillance. The expansion of healthcare infrastructure in developing countries is also facilitating greater access to hepatitis testing. Additionally, the rising investment in research and development for faster and more accurate diagnostic solutions is contributing to market growth. As public health strategies focus on early detection and prevention of viral hepatitis, the hepatitis E diagnostic tests market is poised for substantial expansion.

SCOPE OF STUDY:

The report analyzes the Hepatitis E Diagnostic Tests market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (ELISA HEV IGM Tests Type, ELISA HEV IGG Tests Type, Rapid Diagnostics Tests Type, Polymerase Chain Reaction Type); End-Use (Hospitals End-Use, Diagnostics Laboratories End-Use, Blood Banks End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â